• Salix Pharmaceuticals Ltd., of Raleigh, N.C., reported a GAAP net income of $17.6 million, or $0.28 per share, fully diluted, for the fourth quarter of 2012 and $64.2 million, or $1.01 per share, fully diluted, for the full year ended Dec. 31, 2012.